Background: Historically, baseline neutropenia and lack of neutrophil recovery have been associated with poor outcomes in invasive aspergillosis (IA). It is unclear how treatment with the new Aspergillus-active triazoles isavuconazole and voriconazole affects outcomes in neutropenic patients with IA.
Introduction
Invasive aspergillosis (IA) has become the predominant mycosis in patients with haematological cancer and prolonged neutropenia. 1 Historically, prolonged neutropenia was associated with a failure to respond to antifungal therapy as well as increased mortality in patients with haematological malignancies, although the data come mostly from older, single-institution, retrospective studies that relied on culture-or histopathology-proven IA cases in which the outcomes were poor. [1] [2] [3] Pivotal randomized studies for the treatment of IA in the last two decades showed improvement of responses with triazoles, 3 -5 yet they do not provide an in-depth evaluation of the impact of neutropenia on IA outcomes. The significance of persistent neutropenia for outcomes in IA is a timely question in the era of high-potency new anti-Aspergillus triazoles, such as isavuconazole and voriconazole, and revised guidelines for the diagnosis of probable IA that heavily rely on Aspergillus galactomannan (GM) detection. Specifically, a potential confounder for V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com. improved outcome in the latest studies might have been the introduction of Aspergillus GM in serum or bronchoalveolar lavage samples, which is an important step in the early diagnosis of IA. 6 The SECURE trial demonstrated the non-inferiority of isavuconazole compared with voriconazole for the treatment of IA and other filamentous fungi. 5 In this post hoc analysis of the SECURE trial, we compared the efficacy and safety outcomes in the subset of patients with baseline neutropenia and IA in order to assess the impact of persistent neutropenia on mortality and outcomes in each treatment group. We also examined the impact of baseline GM on outcomes for each treatment arm.
Methods

Study design
The SECURE trial (ClinicalTrials.gov; NCT00412893) was a global, Phase 3, randomized, multicentre, double-blind, comparative-group, non-inferiority trial of isavuconazole versus voriconazole. 5 The primary findings of this trial together with methodology and patient eligibility criteria have been reported elsewhere.
5 Briefly, patients aged 18 years with proven, probable or possible invasive fungal infections, defined according to the criteria of the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group, 7 were randomized 1:1 to receive isavuconazole or voriconazole. Patients assigned to isavuconazole received a loading dose of 372 mg of isavuconazonium sulphate prodrug, equivalent to 200 mg of isavuconazole, three times daily intravenously for the first 2 days, followed by a maintenance once-daily intravenous or oral dose of 200 mg of isavuconazole from day 3 to end of treatment (EOT). Patients assigned to voriconazole received a loading dose of 6 mg/kg every 12 h intravenously on study day 1, followed by a maintenance dose of 4 mg/kg every 12 h intravenously or 200 mg every 12 h orally from day 2 to EOT.
Patients were treated for up to a maximum of 84 days. The final followup visit was scheduled at 4 weeks +7 days after the last dose of study drug, which may have occurred before or after day 42 and/or day 84.
The primary endpoint of this post hoc analysis was all-cause mortality (ACM) through day 42 following primary treatment with isavuconazole compared with voriconazole in patients with neutropenia and IA. Differences in the primary outcome by neutropenic status and treatment assignment, for patients with neutropenia at baseline that had resolved or remained at day 7, day 42 and EOT, were also assessed. Overall success at EOT was a key secondary endpoint and was based on clinical, mycological and radiological responses as described previously. 5 The impact of baseline GM on outcomes in each treatment arm was evaluated.
Assessments
Mycological assessments were performed locally according to best practice and included samples for fungal culture and isolation and biopsy/biological fluid samples from the infected site for histology/cytology. Serum samples were assessed for Aspergillus infection by GM antigen assay, with a single value 0.7 or two consecutive values 0.5 by Bio-Rad Platelia TM (Bio-Rad, Hercules, CA, USA) considered a positive result.
An independent data review committee (DRC) assessed proven or probable IA status and evaluated clinical, mycological and overall response at EOT based on consensus criteria. 8 Specifically, complete or partial clinical success was defined as the complete resolution or partial resolution, respectively, of attributable clinical symptoms and physical findings. Clinical failure was defined as no resolution of any attributable clinical symptoms and physical findings and/or worsening of symptoms or results not available. Mycological success was defined as eradication, or presumed eradication, of infection, and failure as cases of persistence or presumed persistence of infection.
Neutropenic status was determined at baseline, day 7, day 42 and EOT. Neutropenia was defined as an absolute neutrophil count (ANC)
,0.5%10 9 /L for .10 days at baseline. For measurements on or before day 7, unresolved neutropenia was defined as no ANC measurement available or at least one ANC ,0.5%10 9 /L measurement. For day 42 and EOT measurements, unresolved neutropenia was defined as no ANC measurement in patients whose previously available ANC indicated neutropenia, or at least one ANC ,0.5%10 9 /L measurement from day 35 to day 49, or from 3 days before to 3 days after last treatment dose, respectively.
Patients whose neutropenia had resolved were compared with those who remained neutropenic (unresolved neutropenia). A comparison of the efficacy and safety of isavuconazole compared with voriconazole was also carried out for these patient groups.
The incidence, nature and severity of treatment-emergent adverse events (TEAEs) were monitored and assessed throughout the study for all patients who received one or more doses of study drug.
Analysis populations
This analysis was performed using the mycological ITT (myITT) population, which included all patients with neutropenia and proven or probable IA, as assessed by the DRC, who had received at least one dose of study drug.
Statistical analyses
Demographic and baseline characteristics were summarized for the myITT population. The primary efficacy endpoint of crude ACM through day 42 was assessed from the myITT population, with the between-group treatment difference obtained by subtracting the voriconazole rate from isavuconazole rate. Fisher's exact test (two-tailed) (R software, University of Aix-Marseille, France) was used to assess differences between treatment groups and between groups with resolved versus unresolved neutropenia and P , 0.05 was considered significant.
Results
Patient demographics and baseline characteristics
Overall, 142 patients with neutropenia received one or more doses of study drug and had either proven or probable IA, and thus constituted the myITT population. The treatment subgroups were mostly well balanced with respect to age and other baseline characteristics ( Table 1 ). The percentage of males was lower among those assigned to the isavuconazole group, compared with those assigned to the voriconazole group. Nearly all patients had underlying haematological malignant disease, with acute leukaemia accounting for .50% cases in each treatment group (Table 1) . Most patients had active malignancy at the diagnosis of IA (83.3% and 89.1% in the isavuconazole and voriconazole groups, respectively). The majority of patients only had invasive pulmonary aspergillosis (91.0% in the isavuconazole group and 96.9% in the voriconazole group). More patients in the isavuconazole group (2/78) had disseminated IA compared with the voriconazole group (0/64, P " not significant; Table 1 ).
Most aspergillosis diagnoses were based only on positive serum GM (74.4% isavuconazole group, 82.8% voriconazole group) versus isolation of Aspergillus spp. alone and Aspergillus spp. plus other filamentous fungi (25.6% isavuconazole group, 17.2% voriconazole group; Table 2 ). Among those patients with a pathogen identified at baseline, the predominant pathogens causing IA as assessed Kontoyiannis et al. by the DRC were Aspergillus fumigatus and Aspergillus flavus (Table 2) , which accounted for 15.4% of cases in the isavuconazole group and 17.2% of cases in the voriconazole group.
Efficacy outcomes
In the isavuconazole group, neutropenia persisted in 58/78 (74.4%) patients at day 7, 40/78 (51.3%) patients at day 42 and 37/78 (47.4%) patients at EOT. In the voriconazole group, neutropenia persisted in 47/64 (73.4%) patients at day 7, 31/64 (48.4%) patients at day 42 and 33/64 (51.6%) patients at EOT. How the diagnosis of neutropenia was made is shown in Table S1 (available as Supplementary data at JAC Online). Patients who had resolved their neutropenia at day 7 but subsequently relapsed are shown in Table S2 . Overall, 10/20 (50.0%) and 11/17 (64.7%) patients in the isavuconazole and voriconazole groups, respectively, who had resolved neutropenia at day 7 were subsequently diagnosed with unresolved neutropenia at day 42. Similarly, 8/20 (40.0%) and 7/17 (41.2%) patients in the isavuconazole and voriconazole groups, respectively, who had resolved neutropenia at day 7 subsequently were diagnosed with unresolved neutropenia at EOT. The relapse in neutropenia was predominantly due to the lack of availability of absolute neutrophil counts at these timepoints (Table S2) .
In patients who were neutropenic at baseline, overall ACM at day 42 occurred in 19/78 (24.4%) patients (18/58 patients with unresolved neutropenia at day 7 and 1/20 patients with resolved neutropenia at day 7) in the isavuconazole group and 15/64 (23.4%) patients (14/47 patients with unresolved neutropenia at day 7 and 1/17 patients with resolved neutropenia at day 7) in the voriconazole group ( (Table 3) .
Although the numbers were small, ACM was slightly higher in patients with unresolved neutropenia regardless of treatment arm at day 7 and day 42 when diagnosis was based upon culture plus GM positivity, compared with culture-negative GM positivity (day 7, 8/22 versus 24/83; day 42, 8/17 versus 24/54, respectively; Table 3 ). There was a statistically significant association between baseline GM values and the risk of mortality in the isavuconazole group at day 42, with 0/12 patients in the 0.5 to 1.0 group, compared with 15/44 (34.1%) (P " 0.024) in the .1.0 group, and at EOT with 0/12 patients in the 0.5 to 1.0 group, compared with 18/44 (40.9%) (P " 0.006) in the .1.0 group, progressing to death (Table 4 ). In contrast, no significant link was observed in the voriconazole group.
In line with the ACM results, the finding of DRC-assessed treatment success at EOT was greater in patients with resolved, compared with those with unresolved, neutropenia at all timepoints, regardless of treatment group. Isavuconazole achieved rates of success similar to those of voriconazole in those stratified according to unresolved or resolved neutropenia status at day 7 and at day 42 but not at EOT (Table 5) . At EOT, voriconazole appeared to have a greater success rate among those with unresolved neutropenia while isavuconazole appeared to have a greater success rate in those with resolved neutropenia. Overall, there were no differences between treatment groups at EOT [success in the isavuconazole group 19/58 (32.8%) versus voriconazole 16/47 (34.0%)].
Discussion
Using a post hoc analysis of the large Phase 3 SECURE trial, we report the largest contemporary dataset to date assessing the impact of neutropenia resolution on outcomes in patients with IA treated with the modern triazoles, isavuconazole and voriconazole, that are endorsed by guidelines as the preferred first-line agents.
1 Failure to resolve neutropenia was a major factor for ACM regardless of the treatment group and is a major finding of our study. We also found that isavuconazole had similar efficacy to voriconazole in patients with baseline neutropenia, irrespective of whether neutropenia had resolved or remained at day 7, day 42 or EOT. However, poorer outcomes were observed for both drugs in the setting of persistent neutropenia. This suggests that neutropenia continues to be a predictor of poor outcomes in patients with IA, and that persistence of neutropenia could potentially influence outcomes in clinical trials. Unresolved neutropenia at EOT defined as no ANC measurement available or at least one ANC ,0.5%10 9 /L measurement from 3 days before last dose to 3 days after last dose.
Kontoyiannis et al.
A number of studies have identified neutropenia as a risk factor for mortality and response to therapy in IA. [9] [10] [11] [12] [13] [14] Neutrophils are crucial for host protection against aspergillosis as they have a direct role in the destruction of hyphae and prevent germination of conidia. 15, 16 Delayed engraftment after stem cell transplantation and prolonged neutropenia are strong predictors of both IA and poor outcome. 17 In a study of patients with haematological malignancies, Reuter et al. 18 found that patients with neutropenia of 5 days had a 12 month survival rate of 92%, compared with 58% for those with persistent neutropenia of .10 days. Our study emphasizes the importance of resolving neutropenia in patients with IA, even in the era of early GM-based diagnosis of IA and the use of potent triazoles. Indeed, there was no further ACM at day 42 in patients whose neutrophil counts recovered. Therefore, early restoration of neutrophil count is an important consideration in the management of patients with IA. Whether the inferior outcomes of neutropenia reflect the fact that voriconazole and isavuconazole are static drugs in the doses currently used against Aspergillus spp. is a theoretical, yet tenable, hypothesis. [19] [20] [21] In our analysis of patients who were neutropenic at baseline, the overall day 42 ACM rates of 24.4% (isavuconazole) and 23.4% (voriconazole) were slightly lower than those of previous studies Unresolved neutropenia at EOT defined as no ANC measurement available or at least one ANC ,0.5%10 9 /L measurement from 3 days before last dose to 3 days after last dose.
IA treatment and persistent neutropenia JAC that reported 6 and 12 week mortality data on the order of 27%-30% when voriconazole was used as primary monotherapy treatment of IA in patients with haematological diseases and haematopoietic stem cell transplantation, 3,4,22 although not all patients in these older studies had neutropenia. In the current study, similar overall treatment success rates at EOT were observed between isavuconazole-and voriconazole-treated patients with neutropenia. At EOT, success was greater in those with resolved versus persistent neutropenia. Although the numbers were small, intriguingly, voriconazole appeared to have a better success rate among those with unresolved neutropenia while isavuconazole appeared to have a greater success rate in those with resolved neutropenia. Whether there are differences in the intracellular concentration of each azole in neutrophils and its immunomodulatory effect (favouring isavuconazole) or a more inherent fungicidal effect of voriconazole in the absence of neutrophils (favouring voriconazole) is a complex question that requires careful experimental testing. Alternatively, this might reflect some imbalances in the population. For example, disseminated IA was more common in the isavuconazole group, compared with the voriconazole group, and may not have been balanced between the resolved and unresolved neutropenia groups.
Not surprisingly, most of the patients in our study had haematological cancer and had a diagnosis of probable IA, on the basis of a positive GM in serum and/or bronchoalveolar lavage. A number of studies have shown that GM values may be a surrogate marker for mortality due to IA, with high GM values being a predictor of mortality in patients with neutropenia.
6,23-26 Furthermore, a diagnosis based on a positive culture together with GM positivity has been shown in a multivariate analysis to be independently associated with an increased risk of death. 27 Our study did not show any significant differences in the risk of death between culture-positive and GM-alone diagnosis.
In our study, irrespective of neutropenia status, there was a link between baseline GM values and ACM in patients receiving isavuconazole, but not in patients who received voriconazole. Furthermore, others have shown that patients with IA regardless of neutropenia status whose GM values normalize after initiation of antifungal therapy, including isavuconazole, have significantly better outcomes compared with patients with persistently positive GM values.
6, [23] [24] [25] [26] 28 Future clinical trials on IA should consider sequential GM values during treatment as a possible surrogate marker for success.
As a post hoc analysis, this study has inherent limitations, including a limited analysis population that may have resulted in sampling bias and/or introduced imbalances and a lack of powering to support firm conclusions. In addition, as the study enrolment criteria excluded patients who were severely ill, and with comorbidities such as renal or hepatic dysfunction, there might be limitations in the generalizability of our findings.
In conclusion, the findings of this post hoc analysis of the Phase 3 SECURE trial suggest that isavuconazole has comparable efficacy to voriconazole in the primary treatment of IA in patients with either resolved or unresolved neutropenia. These data confirm the durable influence of resolving neutropenia on improving antifungal treatment success and outcomes in patients with haematological cancer and IA. Similar observations of the profound influence of neutrophil recovery on outcome have been made for the other clinically important, yet less common non-Aspergillus moulds that cause invasive fungal infections in this patient population. [29] [30] [31] Future studies should carefully analyse and report outcomes of agents by taking the issue of persistent neutropenia into account. Finally, whether there are meaningful differences in the activity of voriconazole compared with isavuconazole in patients with IA and unresolved neutropenia would require further study.
